Novel and Unique ELISA for Measuring Amyloid-Beta Toxic Oligomer
Posted by Gabriel Koehler on Nov 9th 2016
A novel and unique ELISA for measuring Amyloid Beta Toxic Oligomer #27709 Human Amyloidβ Toxic Oligomer Assay Kit will be released in November 2016. This ELISA is designed using the N-terminal specific antibody (clone: 82E1) as the capture antibody and the detection antibody (clone: 24B3) specifically reacts to position E22 and D23 (turned position) that is identified as a toxic conformer. This kit specifically measures human Amyloid-Beta Toxic conformers that have a turn at position 22 and 23 in CSF.
Amyloid Hypothesis for Alzheimer’s Disease
It has been considered that senile plaques that consist mainly of Beta Amyloid 40 ( Aβ 40 ) and 42 ( Aβ 42 ) proteins is a hallmark of Alzheimer’s disease (AD) (Fig.1). However, it has been reported that senile plaques are also found in the dead brains of healthy aging people. This means that senile plaques may be only one of the major phenomenon of aging and/or Alzheimer’s disease.
Beta Amyloid 42 Toxic Oligomer
Oligomerization of Aβ 40 and Aβ 42 can been seen in an early stage of AD. Dimers and trimers of Aβ 40 and Aβ 42 are aggregated to be formed as Beta Amyloid Oligomers and eventually become Amyloid fibrils via oligomers or protofibrils. According to many studies results, in general, it has been considered among researchers that (1) Aβ 42 is more neurotoxic than Aβ40 and (2) soluble Oligomers are more neurotoxic than insoluble Aβ such as Amyloid fibrils.
Potential Biomarker for AD diagnosis
According to the study published by Murakami K et al. Sci Rep. 2016 Jul 4; 6: 29038., the ratio of toxic to total Beta Amyloid 42 in CSF of AD patients is significantly higher than in control subjects as measured by the
ELISA kit #27709 Human Amyloidβ Toxic Oligomer Assay Kit. (Fig.2)
More details of this study are available from the following publication. Monoclonal antibody with conformational specificity for a toxic conformer of amyloid β42 and its application toward the Alzheimer's disease diagnosis. Murakami K et al. Sci Rep. 2016 Jul 4; 6: 29038. PMID: 27374357
https://www.ncbi.nlm.nih.gov/pubmed/?term=27374357
Product Introduction at Neuroscience 2016
This product will be introduced at Neuroscience 2016 in San Diego.
Please visit our booth #3315.
Exhibition: November 13th to November 16th
Venue: The San Diego Convention Center
Search IBL America's other Amyloid Beta and APP related products